Patents by Inventor Antje WEGENER

Antje WEGENER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RADIOLABELLED ALPHA-V BETA-3 AND/OR ALPHA-V BETA-5 INTEGRINS ANTAGONIST FOR USE AS THERAGNOSTIC AGENT
    Publication number: 20240050597
    Abstract: The present disclosure relates to ?v?3 and/or ?v?5 integrins antagonist radiopharmaceuticals and their use in a theragnostic approach for selection and therapy of human subjects with tumors overexpressing ?v?3 and/or ?v?5 integrins. In particular, the present disclosure relates to a pharmaceutical composition of ?v 177Lu radiolabeled ?v?3 and/or ?v?5 integrins antagonist, for use in treating tumors overexpressing ?v?3 and/or ?v?5 integrins in a human subject eligible for said treatment, wherein said subject has been selected for the treatment by PET/CT or PET/MRI or SPECT/CT or SPECT/MRI imaging with the same ?v?3 and/or ?v?5 integrins antagonist but with 68-Ga as radiometal for use as imaging agent.
    Type: Application
    Filed: December 20, 2021
    Publication date: February 15, 2024
    Applicants: ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA, ADVANCED ACCELERATOR APPLICATIONS (ITALY) SRL, NOVARTIS AG
    Inventors: Valeria MUZIO, Antje WEGENER, John Scott CAMERON, Francesco DE CARLI, Paola BARDINI, Alessandro MAGRI, Mattia ROSSETTO, Daniela BARENGO
  • RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC
    Publication number: 20230321287
    Abstract: The present disclosure relates to gastrin-releasing peptide receptor (GRPR) targeting pharmaceuticals and their use in a theragnostic approach for selection and therapy of subjects with GRPR-expressing malignancies. In particular, the present disclosure relates to a pharmaceutical composition of a radiolabeled GRPR-antagonist, for use in treating GRPR-positive tumors in a human subject selected for said treatment, wherein said subject has been selected for the treatment by PET/CT or PET/MRI imaging with a corresponding 68Ga-labelled GRPR antagonist as contrast agent.
    Type: Application
    Filed: September 23, 2020
    Publication date: October 12, 2023
    Inventors: Daniela CHICCO, Maurizio F. MARIANI, Francesca ORLANDI, Antje WEGENER